Andrographis: Cold Relief, Immune Support & the Hepatotoxicity Warning — A Research-Backed Guide
60-Second Summary
Andrographis (Andrographis paniculata) — called "King of Bitters" in Ayurveda — is one of the most clinically studied herbs for upper respiratory tract infections. Its key active compound, andrographolide, inhibits NF-kB signaling, reduces pro-inflammatory cytokines, and modulates innate immune cell activity. The evidence for reducing cold and flu duration and symptom severity is moderate and replicated.
Critical safety note: Andrographis is approved only for short-term acute use (5–10 days). Chronic use at high doses is linked to elevated liver enzymes and rare hepatotoxicity. Do not use long-term without medical supervision.
Typical dose: 30–60 mg andrographolide/day (or 3–6 g dried herb) for up to 10 days, started at symptom onset. The Kan Jang formula has the most replicated clinical evidence.
What is andrographis?
Andrographis paniculata is a small annual herbaceous plant in the Acanthaceae family, native to South and Southeast Asia. It has been used in Ayurvedic and traditional Chinese medicine for centuries, primarily for fever, upper respiratory infections, diarrhea, and liver complaints. Its intensely bitter taste gives rise to its common name "King of Bitters."
The plant's primary bioactive compounds are andrographolides — bicyclic diterpene lactones. Andrographolide is the most abundant and most studied; neoandrographolide and 14-deoxy-11,12-didehydroandrographolide are secondary compounds that contribute to overall activity. Andrographolide's main mechanism is inhibition of the NF-kB transcription factor, which controls the expression of many pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and viral replication signals.
Evidence-based benefits
1. Upper respiratory tract infection — symptom relief
This is andrographis's best-supported clinical use. A 2004 systematic review (Poolsup et al.) covering six RCTs found that andrographis preparations significantly reduced overall symptom severity scores for uncomplicated upper respiratory tract infections compared with placebo, with an effect size of approximately 0.5–0.8 standard deviations. Cold duration was reduced by about 1.2–1.8 days on average. A subsequent 2012 Cochrane review reached similar conclusions. The effect is comparable to some over-the-counter symptomatic cold remedies, but via a different mechanism — immune modulation rather than antihistamine or decongestant action.
2. Reduction in recurrent cold frequency
A 3-month prevention trial using Kan Jang (see below) in Swedish schoolchildren found significantly fewer total days of illness and a lower number of cold episodes versus placebo. This suggests a mild immunomodulatory effect suitable for prevention during high-risk seasons, though prevention evidence is less robust than acute treatment evidence.
3. Anti-inflammatory signaling
Andrographolide potently inhibits NF-kB, cyclooxygenase-2 (COX-2), and 5-lipoxygenase in vitro and in animal models. This pharmacology underpins its traditional use for fever and general inflammation. Human clinical data specifically targeting inflammation (e.g., CRP reduction) are limited to small trials; this use case should be considered preliminary.
4. COVID-19 / antiviral potential (preliminary)
Thai and Indian regulatory authorities authorized compassionate use of andrographolide preparations for mild COVID-19 during the pandemic based on in vitro antiviral activity and small observational studies. This evidence does not meet the bar for a clinical recommendation; andrographolide should not be substituted for proven treatments.
The Kan Jang formula explained
Kan Jang is a proprietary combination of Andrographis paniculata extract (SHA-10 standardized to 4–5.6 mg andrographolide per tablet) and Eleutherococcus senticosus (Siberian ginseng). Originally developed at the Swedish Herbal Institute, Kan Jang has been evaluated in over 10 controlled trials involving more than 1,500 participants across Sweden, Chile, and Russia. The combination formula consistently outperforms placebo for reducing cold symptom duration and severity. The SHA-10 extract has also been tested alone, confirming that andrographis is the primary active constituent.
When evaluating products, look for andrographolide content standardized to match Kan Jang's dosing: approximately 30–60 mg andrographolide per day in divided doses.
Supplement forms compared
| Form | Best for | Typical dose | Notes |
|---|---|---|---|
| Standardized extract (10% andrographolide) | Cold/flu acute treatment | 300–600 mg extract (30–60 mg andrographolide)/day | Most reliable potency. The form used in clinical trials. |
| Kan Jang formula (SHA-10) | Cold/flu acute treatment | Per label (typically 3–6 tablets/day) | Best-validated proprietary preparation; widely available in Scandinavia and online. |
| Dried herb / crude powder | Traditional use | 3–6 g/day | Andrographolide content highly variable (0.5–6%). Less reliable for clinical dosing. |
| Tincture | Flexible dosing | Varies by concentration | Intensely bitter; ensure andrographolide standardization on label. |
Dosage guidance
- Acute cold and flu treatment: 30–60 mg andrographolide/day (or 3–6 g dried herb) in 2–3 divided doses for 5–10 days; begin at symptom onset for best effect
- Prevention (seasonal): Lower doses (15–30 mg andrographolide/day) used in some trials for 3 months; evidence is weaker than acute treatment evidence
- Maximum duration without medical supervision: 10 days. Chronic use is not supported and carries hepatotoxicity risk
Take with food. Andrographis is very bitter — capsules or tablets are strongly preferred over loose powder or raw herb.
Safety and hepatotoxicity risk
At standard short-term doses (5–10 days), andrographis is generally well-tolerated. The most common adverse effects are:
- GI upset — nausea, diarrhea, stomach cramping (especially on an empty stomach)
- Headache and fatigue at higher doses
- Allergic reactions in rare cases (cross-reactivity with other Acanthaceae plants)
Hepatotoxicity — important warning
Case reports from Australia and Sweden describe cholestatic hepatitis and elevated transaminases (AST, ALT) in individuals using andrographis chronically or at high doses. Although hepatotoxicity from andrographis is considered rare, it is documented and clinically significant. Risk increases with:
- Dose above 60 mg andrographolide/day
- Duration beyond 10 days without breaks
- Pre-existing liver disease or concurrent hepatotoxic drugs
- Alcohol use
Do not use andrographis long-term without clinician monitoring of liver enzymes.
Pregnancy and reproductive concerns
Andrographolide has shown antifertility and potential abortifacient effects in animal studies. Andrographis is contraindicated during pregnancy. Avoid in women trying to conceive and during breastfeeding.
Drug interactions
- Immunosuppressants (cyclosporine, azathioprine, corticosteroids): Andrographis stimulates immune function and may counteract immunosuppressive therapy in transplant patients and those with autoimmune conditions. Avoid combination.
- Anticoagulants and antiplatelets (warfarin, aspirin): Theoretical additive antiplatelet effect; monitor INR if concurrent use cannot be avoided.
- Hepatotoxic drugs (statins, acetaminophen at high dose, alcohol): Compounded liver stress risk. Avoid combination or use under strict clinical supervision.
- Antihypertensives: Animal studies suggest mild hypotensive activity; additive effect with antihypertensive medications is possible.
Check our free interaction checker for more.
Who might benefit — and who shouldn't
| Most likely to benefit | Should avoid or use with caution |
|---|---|
| Adults treating early-onset cold or flu symptoms (start within 24–48 hours) | Pregnant or breastfeeding women (contraindicated) |
| Those wanting clinically validated immune support during cold-and-flu season | People with autoimmune conditions (lupus, RA, MS) |
| Adults who prefer evidence-based herbal alternatives to OTC symptomatic cold medicines | Anyone on immunosuppressants or organ transplant recipients |
| Seasonal prevention (short cycles, with breaks) | People with liver disease or on hepatotoxic medications |
Frequently asked questions
Does andrographis actually reduce cold duration?
Yes — the evidence is moderate and replicated. Multiple RCTs and meta-analyses show roughly 1–2 days shorter symptom duration when andrographis is started within the first 48 hours of cold onset. It does not prevent infection but reduces severity and shortens illness.
What is the Kan Jang formula?
Kan Jang is a standardized combination of Andrographis paniculata (SHA-10 extract) and Eleutherococcus senticosus, developed at the Swedish Herbal Institute. It has the strongest clinical evidence base among andrographis products, with 10+ controlled trials. Look for products standardized to the SHA-10 specification (~4–5.6 mg andrographolide per tablet).
Can I use andrographis long-term?
No — andrographis is indicated for short-term acute use (5–10 days) only. Chronic use at high doses is associated with elevated liver enzymes and rare hepatotoxicity. Take breaks between courses and do not use continuously without medical supervision.
Is andrographis safe in autoimmune conditions?
Caution is warranted. Andrographis stimulates immune cell activity and NF-kB-dependent immune responses, which may aggravate autoimmune conditions. People with lupus, rheumatoid arthritis, MS, or other autoimmune diseases should consult their clinician before use.
When should I take andrographis during a cold?
Start as early as possible — ideally within 24–48 hours of the first symptom (sore throat, runny nose, fatigue). Clinical trials show greatest benefit when initiated early. Take with food to minimize GI upset.
Related ingredients and articles
Astragalus
Immune-modulating herb with longer-term preventive evidence for respiratory health.
American Ginseng
Adaptogen with RCT evidence for cold prevention in elderly adults.
Ashwagandha
Adaptogen with cortisol-lowering and immune-supporting evidence for chronic stress.
Boswellia
5-lipoxygenase inhibitor — compare anti-inflammatory mechanisms.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.